Skip to main content
Equibles
PTIX logo

PTIX · Protagenic Therapeutics, Inc.\new · Metrics

Track PTIX — free

Use PTIX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research PTIX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.57 -0.17 (-22.97%) At close · Jan 5
Rebalance outlook locked
Going-concern doubt — flagged Aug 19, 2026

Substantial doubt about the company's ability to continue as a going concern.

“The Company does not have sufficient resources to fund its operations past twelve months from the date these consolidated financial statements are available to be issued. The Company expects that additional capital may be required during the next 12 months to continue executing its business plan and to meet its obligations as they become due. Accordingly, these conditions raise substantial doubt about the Company's ability to continue as a going concern within one year after the date these financial statements are issued.”
View the 10-Q filed Aug 19, 2026
Market Cap
$1.45M
Shares
1.81M
Volume · Jan 5 580.9K Avg daily vol (3M) 120.04K

PTIX metrics

52 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.57
Market cap
$1.45M

Price action

20 metrics
Price change (1W)
-61.7%
Price change (30D)
—
Price change (3M)
-83.2%
Price change (6M)
-83.2%
Price change (YTD)
-56.2%
Price change (1Y)
—
Trailing year
Price change (5Y)
—
52-week high
—
52-week low
—
Change from 52-week high
—
Change from 52-week low
—
Annualized volatility
365.4%
Annualized volatility (3M)
128.3%
Beta
—
RSI (14D)
22.9
Price vs SMA 50
-69.6%
Price vs SMA 200
—
Avg volume (3M)
120,044
Relative volume
4.8
Average dollar volume
$201,510

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
1.81M

Valuation

12 metrics
P / E (TTM)
0.4
Trailing earnings · reciprocal yield 250.9%
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
0.8
reciprocal yield 118.9%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
376.7%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2023-03-31

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$4.26M
Net income (TTM)
$5.46M
Trailing 12 months
Diluted EPS (TTM)
$1.43
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$0.00
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
$-2.30
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
$2.91
Operating cash flow per diluted share (TTM)
$-1.08
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
$0.33
Stock compensation per diluted share (TTM)
$0.19
Book value per share
$0.95

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
$0
Trailing 12 months
EPS growth YoY
—
Shares change YoY
-51.1%
Year over year · fewer shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
316.9%
Return on assets
195.3%
Debt / equity
0.0
Current ratio
0.7
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
—
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$565,985
Latest balance sheet
Cash & equivalents
$565,985
Total assets
$2.80M
Total debt
$0

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$2.00M
Capital expenditures (TTM)
—
R&D (TTM)
$617,709
SG&A (TTM)
—
Stock compensation (TTM)
$360,474
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
2
13F filer change QoQ
-2
Institutional ownership
3.7%
Conviction holders (share of 13F filers)
—
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
0.0%
Active holders' share change QoQ
-0.2%
Holder tenure
—
Price vs estimated holder cost
—

Ownership (registered funds)

1 metrics
Index-fund ownership
0.0%

Short interest

3 metrics
Short interest
—
Latest settlement
Days to cover
—
Short-squeeze score
—

Insider activity

2 metrics
Net insider buying (90D)
$30,717
Insider-sentiment score
84 / 100

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1022899 CUSIP 74365N301 13F (30d) 1 filings 1 filers Visit website Investor relations